Coronavac inactivated vaccine triggers durable, cross-reactive Fc-mediated phagocytosis activities

References

• Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022/03/05;399(10328):924–944. doi:10.1016/S0140-6736(22)00152-0
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022 Jan 7;375(6576):43–50. PubMed PMID: 34812653; PubMed Central PMCID: PMCPMC9017870. doi:10.1126/science.abm3425
   PubMed Web of Science ®Google Scholar
• Fong Y, McDermott AB, Benkeser D, et al. Immune correlates analysis of a single Ad26.COV2.S dose in the ENSEMBLE COVID-19 vaccine efficacy clinical trial. medRxiv. 2022 Apr 12. PubMed PMID: 35441174; PubMed Central PMCID: PMCPMC9016647. doi:10.1101/2022.04.06.22272763
   PubMedGoogle Scholar
• McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect Dis. 2022 2022/10/01;22(10):1435–1443. doi:10.1016/S1473-3099(22)00345-0
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020 Nov 12;383(20):1920–1931. PubMed PMID: 32663912; PubMed Central PMCID: PMCPMC7377258. doi:10.1056/NEJMoa2022483
   PubMed Web of Science ®Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 Aug 15;396(10249):467–478. PubMed PMID: 32702298; PubMed Central PMCID: PMCPMC7445431. doi:10.1016/S0140-6736(20)31604-4
   PubMed Web of Science ®Google Scholar
• Stephenson KE, Le Gars M, Sadoff J, et al. Immunogenicity of the Ad26.COV2.S vaccine for COVID-19. JAMA. 2021;325(15):1535–1544. doi:10.1001/jama.2021.3645
   PubMed Web of Science ®Google Scholar
• Lu LL, Suscovich TJ, Fortune SM, et al. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. 2018 Jan;18(1):46–61. PubMed PMID: 29063907; PubMed Central PMCID: PMCPMC6369690. doi:10.1038/nri.2017.106
   PubMed Web of Science ®Google Scholar
• Boudreau CM, Alter G. Extra-Neutralizing FcR-mediated antibody functions for a universal influenza vaccine. Front Immunol. 2019;10:440. PubMed PMID: 30949165; PubMed Central PMCID: PMCPMC6436086. doi:10.3389/fimmu.2019.00440
   PubMed Web of Science ®Google Scholar
• Bournazos S, Chow SK, Abboud N, et al. Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. J Clin Invest. 2014 Feb;124(2):725–729. PubMed PMID: 24401277; PubMed Central PMCID: PMCPMC3904629. doi:10.1172/JCI72676
   PubMed Web of Science ®Google Scholar
• Suscovich TJ, Fallon JK, Das J, et al. Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01 vaccination. Sci Transl Med. 2020 Jul 22;12(553). PubMed PMID: 32718991. doi:10.1126/scitranslmed.abb4757
   PubMed Web of Science ®Google Scholar
• Meyer M, Gunn BM, Malherbe DC, et al. Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects. Sci Transl Med. 2021 Jul 14;13(602). PubMed PMID: 34261800; PubMed Central PMCID: PMCPMC8675601. doi:10.1126/scitranslmed.abg6128
   Web of Science ®Google Scholar
• Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007 Sep 6;449(7158):101–104. PubMed PMID: 17805298. doi:10.1038/nature06106
   PubMed Web of Science ®Google Scholar
• Atyeo C, Fischinger S, Zohar T, et al. Distinct early serological signatures track with SARS-CoV-2 survival. Immunity. 2020 Sep 15;53(3):524–532 e4. PubMed PMID: 32783920; PubMed Central PMCID: PMCPMC7392190. doi:10.1016/j.immuni.2020.07.020
   PubMed Web of Science ®Google Scholar
• Zohar T, Loos C, Fischinger S, et al. Compromised humoral functional evolution tracks with SARS-CoV-2 mortality. Cell. 2020 Dec 10;183(6):1508–1519 e12. PubMed PMID: 33207184; PubMed Central PMCID: PMCPMC7608014. doi:10.1016/j.cell.2020.10.052
   PubMed Web of Science ®Google Scholar
• Winkler ES, Gilchuk P, Yu J, et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell. 2021 Apr 1;184(7):1804–1820 e16. PubMed PMID: 33691139; PubMed Central PMCID: PMCPMC7879018. doi:10.1016/j.cell.2021.02.026
   PubMed Web of Science ®Google Scholar
• Hassan AO, Shrihari S, Gorman MJ, et al. An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. Cell Rep. 2021 Jul 27;36(4):109452. PubMed PMID: 34289385; PubMed Central PMCID: PMCPMC8270739. doi:10.1016/j.celrep.2021.109452
   PubMed Web of Science ®Google Scholar
• Ullah I, Prevost J, Ladinsky MS, et al. Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity. 2021 Sep 14;54(9):2143–2158 e15. PubMed PMID: 34453881; PubMed Central PMCID: PMCPMC8372518. doi:10.1016/j.immuni.2021.08.015
   PubMed Web of Science ®Google Scholar
• Kaplonek P, Cizmeci D, Fischinger S, et al. mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions. Sci Transl Med. 2022 May 18;14(645):eabm2311. PubMed PMID: 35348368; PubMed Central PMCID: PMCPMC8995030. doi:10.1126/scitranslmed.abm2311
   PubMed Web of Science ®Google Scholar
• Chen Y, Tong X, Li Y, et al. A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients. PLoS Pathog. 2020 Sep;16(9):e1008796. PubMed PMID: 32913364; PubMed Central PMCID: PMCPMC7482996. doi:10.1371/journal.ppat.1008796
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen L, Yin S, et al. The third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 delta and omicron variants. Emerg Microbes Infect. 2022 Dec;11(1):1524–1536. PubMed PMID: 35608053; PubMed Central PMCID: PMCPMC9176682. doi:10.1080/22221751.2022.2081614
   PubMed Web of Science ®Google Scholar
• Tao Y, Ma M, Hu F, et al. A longitudinal study of humoral immune responses induced by a 3-dose inactivated COVID-19 vaccine in an observational, prospective cohort. BMC Immunol. 2022 Nov 16;23(1):57. PubMed PMID: 36384440; PubMed Central PMCID: PMCPMC9666991. doi:10.1186/s12865-022-00532-1
   PubMed Web of Science ®Google Scholar
• Chen Y, Shen H, Huang R, et al. Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac. Lancet Infect Dis. 2021 2021/08/01;21(8):1071–1072. doi:10.1016/S1473-3099(21)00287-5
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science (New York, NY). 2020 Mar 13;367(6483):1260–1263. PubMed PMID: 32075877; PubMed Central PMCID: PMCPMC7164637. doi:10.1126/science.abb2507
   Google Scholar
• Li T, Han X, Gu C, et al. Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants. Nat Commun. 2021 2021/11/02;12(1):6304. doi:10.1038/s41467-021-26539-7
   PubMed Web of Science ®Google Scholar
• Butler AL, Fallon JK, Alter G. A sample-sparing multiplexed ADCP assay. Front Immunol. 2019;10:1851. PubMed PMID: 31456799; PubMed Central PMCID: PMCPMC6700248. doi:10.3389/fimmu.2019.01851
   PubMed Web of Science ®Google Scholar
• Karsten CB, Mehta N, Shin SA, et al. A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis. J Immunol Methods. 2019 Aug;471:46–56. PubMed PMID: 31132351; PubMed Central PMCID: PMCPMC6620195. doi:10.1016/j.jim.2019.05.006
   PubMed Web of Science ®Google Scholar
• Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022 Aug;608(7923):593–602. PubMed PMID: 35714668; PubMed Central PMCID: PMCPMC9385493. doi:10.1038/s41586-022-04980-y
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kruger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022 Feb 3;185(3):447–456 e112. PubMed PMID: 35026151; PubMed Central PMCID: PMCPMC8702401. doi:10.1016/j.cell.2021.12.03
   PubMed Web of Science ®Google Scholar
• Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022 Feb;23(2):186–193. PubMed PMID: 35105982. doi:10.1038/s41590-021-01122-w
   PubMed Web of Science ®Google Scholar
• Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020 Aug 14;369(6505):806–811. PubMed PMID: 32434945; PubMed Central PMCID: PMCPMC7243363. doi:10.1126/science.abc6284
   PubMed Web of Science ®Google Scholar
• Mok CKP, Cohen CA, Cheng SMS, et al. Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. Respirology. 2022 Apr;27(4):301–310. PubMed PMID: 34820940; PubMed Central PMCID: PMCPMC8934254. doi:10.1111/resp.14191
   PubMed Web of Science ®Google Scholar
• Bartsch YC, Tong X, Kang J, et al. Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines. Sci Transl Med. 2022 Apr 27;14(642):eabn9243. PubMed PMID: 35289637; PubMed Central PMCID: PMCPMC8995028. doi:10.1126/scitranslmed.abn9243
   PubMed Web of Science ®Google Scholar
• Tong X, McNamara RP, Avendano MJ, et al. Waning and boosting of functional humoral immunity to SARS-CoV-2. bioRxiv. 2022 Jul 25. PubMed PMID: 35923313; PubMed Central PMCID: PMCPMC9347272 Systems and Leyden Labs. GA has served as a scientific advisor for Sanofi Vaccines. GA has collaborative agreements with GSK, Merck, Abbvie, Sanofi, Medicago, BioNtech, Moderna, BMS, Novavax, SK Biosciences, Gilead, and Sanaria. RAM has served as a scientific advisor for Valneva SE. doi:10.1101/2022.07.22.501163
   Google Scholar
• Richardson SI, Manamela NP, Motsoeneng BM, et al. SARS-CoV-2 beta and delta variants trigger Fc effector function with increased cross-reactivity. Cell Rep Med. 2022 Feb 15;3(2):100510. PubMed PMID: 35233544; PubMed Central PMCID: PMCPMC8761540. doi:10.1016/j.xcrm.2022.100510
   PubMedGoogle Scholar
• Ju B, Fan Q, Wang M, et al. Antigenic sin of wild-type SARS-CoV-2 vaccine shapes poor cross-neutralization of BA.4/5/2.75 subvariants in BA.2 breakthrough infections. Nat Commun. 2022 Nov 19;13(1):7120. PubMed PMID: 36402756; PubMed Central PMCID: PMCPMC9675777. doi:10.1038/s41467-022-34400-8
   PubMed Web of Science ®Google Scholar
• Richardson SI, Madzorera VS, Spencer H, et al. SARS-CoV-2 omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. Cell Host Microbe. 2022 Jun 8;30(6):880–886 e4. PubMed PMID: 35436444; PubMed Central PMCID: PMCPMC8947963. doi:10.1016/j.chom.2022.03.029
   PubMed Web of Science ®Google Scholar